BSE Live
Oct 10, 16:01Prev. Close
5476.10
Open Price
5453.70
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 10, 15:59Prev. Close
5480.50
Open Price
5480.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
5454.50 (2)
Profit & Loss account of Alkem Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 8,653.65 | 9,518.64 | 8,894.16 | 8,829.81 | 7,088.08 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 8,653.65 | 9,518.64 | 8,894.16 | 8,829.81 | 7,088.08 | |
Total Operating Revenues | 8,813.44 | 9,747.72 | 9,054.55 | 8,829.81 | 7,219.68 | |
Other Income | 507.06 | 305.99 | 266.29 | 199.89 | 190.01 | |
Total Revenue | 9,320.50 | 10,053.71 | 9,320.84 | 9,029.70 | 7,409.69 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 2,395.92 | 2,749.93 | 2,629.78 | 2,849.75 | 2,046.52 | |
Purchase Of Stock-In Trade | 389.61 | 1,128.70 | 943.13 | 1,077.04 | 919.79 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | 56.61 | -71.31 | 257.73 | -360.90 | -301.29 | |
Employee Benefit Expenses | 1,630.96 | 1,560.28 | 1,516.22 | 1,434.49 | 1,158.72 | |
Finance Costs | 76.11 | 81.91 | 86.40 | 37.90 | 42.93 | |
Depreciation And Amortisation Expenses | 283.61 | 244.35 | 229.85 | 218.98 | 198.93 | |
Other Expenses | 2,184.14 | 2,414.99 | 2,330.74 | 2,019.07 | 1,447.01 | |
Total Expenses | 7,016.96 | 8,108.85 | 7,993.85 | 7,276.33 | 5,512.61 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 2,303.54 | 1,944.86 | 1,326.99 | 1,753.37 | 1,897.08 | |
Exceptional Items | 0.00 | -63.83 | 0.00 | 0.00 | -12.78 | |
Profit/Loss Before Tax | 2,303.54 | 1,881.03 | 1,326.99 | 1,753.37 | 1,884.30 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 350.13 | 333.28 | 227.52 | 303.82 | 331.83 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -136.31 | -199.40 | -35.00 | -91.70 | -132.61 | |
Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 213.82 | 133.88 | 192.52 | 212.12 | 199.22 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 2,089.72 | 1,747.15 | 1,134.47 | 1,541.25 | 1,685.08 | |
Profit/Loss From Continuing Operations | 2,089.72 | 1,747.15 | 1,134.47 | 1,541.25 | 1,685.08 | |
Profit/Loss For The Period | 2,280.89 | 1,747.15 | 1,134.47 | 1,541.25 | 1,685.08 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 190.77 | 146.13 | 94.88 | 128.90 | 140.93 | |
Diluted EPS (Rs.) | 190.77 | 146.13 | 94.88 | 128.90 | 140.93 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 502.17 | 538.04 | 526.09 | 418.48 | 334.78 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Equity Dividend Rate (%) | 2,250.00 | 2,000.00 | 2,500.00 | 1,700.00 | 1,500.00 |
29.09.2025
23.09.2025
19.09.2025
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
12.08.2025
Q1 Results impact: Alkem Labs, PN Gadgil shares rally up to 10% on strong earnings, Granules up 4%
12.06.2025
Alkem Lab Standalone March 2025 Net Sales at Rs 2,044.94 crore, down 13.55% Y-o-Y
05.06.2025
Alkem Lab Consolidated March 2025 Net Sales at Rs 3,143.75 crore, up 7.08% Y-o-Y
12.07.2023
Alkem Laboratories Q1 PAT seen up 135.1% YoY to Rs 299.7 cr: Nirmal Bang
17.10.2018
Alkem Labs Q2 PAT may dip 30.2% YoY to Rs. 220 cr: HDFC Securities
20.04.2018
Alkem Labs Q4 PAT may dip 1.5% YoY to Rs. 130 cr: HDFC Securities
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key